Vaccine adjuvants that can induce robust protective immunity are highly sought after for the development of safer and more effective vaccines. Vaccine formulation parameters that govern efficacy are still far from clear, such as the diverse impacts of codelivering agonist molecules for innate cell receptors (i.e., pattern recognition receptors, PRRs). In this study, a mesoporous silica (MS)-templating approach is used to fabricate protein antigen (ovalbumin) particles covalently functionalized with agonists for NOD-like receptor 2 (NOD2) and Tolllike receptor 9 (TLR9). Particle-induced combinatorial NOD2/TLR9 signaling results in synergistic inflammatory cytokine secretion by mouse macrophages (RAW 264.7).
Introduction
Most vaccine formulations require adjuvants to induce immune responses that are sufficient to result in protective immunity. Aluminum salt-and emulsion-based adjuvants used in currently licensed vaccine formulations induce primarily humoral immune responses characterized by antibody production and T helper 2 (Th2) cells, which predominantly produce the cytokine interleukin (IL)-4. [1] However, these types of responses are not sufficient for protection against many chronic infections (e.g., HIV) and cancers, which require robust cell-mediated responses carried out by T helper 1 (Th1) and CD8+ T cells, which predominantly produce the cytokine interferon (IFN)-γ. [2] The quantity and quality of T cell activation relies on recognition by innate immune cells via pattern recognition receptors (PRRs). The agonists of many PRRs have been identified and recent studies have shown that PRRs can be activated to induce specific types of immune responses that can be synergistically enhanced through coactivation of various PRR combinations. [3, 4] Two of the most widely studied classes of PRRs are toll-like receptors (TLRs) and NODlike receptors (NLRs), which are transmembrane and cytosolic receptors, respectively. TLRs are localized on the surface and/or endosomal membranes of innate immune cells and recognize microbial patterns that are common to both commensal and pathogenic microbes.
Cytosolic PRRs (e.g., NODs) can detect signals deriving from intracellular infection, which may be an important aspect of the immune system's ability to distinguish between commensal and pathogenic organisms. [5] Of the known PRR ligands, TLR ligands have been the most extensively studied for use in adjuvant formulations, with many in clinical trials and one on the market. [6] The more recently discovered NOD agonists are also currently under investigation for use as adjuvants. [7] Administration of endosomal TLR agonists typically polarizes Th1 [4, 8] and CD8+ T cell [9, 10] responses while NOD agonists polarize primarily Th2 responses. [11] However, recent studies have shown that NOD signaling is crucial for optimal 4 induction of both Th1 and Th2 immune responses upon administration of Complete Freund's Adjuvant (CFA), which contains both TLR and NOD agonists; [11] suggesting that NOD signaling plays different roles in shaping adaptive immunity depending on coactivation of TLRs. Several recent studies have shown that simultaneous stimulation of NODs and TLRs synergistically enhances innate inflammatory immune responses, confirming the existence of crosstalk between TLRs and NODs, which may be beneficial for use in vaccine adjuvants. [3, 12, 13] Recently, Pavot et al. reported an investigation of a NOD/TLR adjuvant system using a chimeric ligand containing a TLR2 and NOD2 agonist. [13] The chimeric ligand synergistically enhanced innate immune responses in both human and mouse dendritic cells (DCs) in vitro and Th1-polarized serum antibody production following subcutaneous administration.
However, responses induced by single agonists were not strong enough to elucidate the potentially complex roles of NOD signaling. Systems that enable the delineation of single and combinatorial PRR signaling are required to fully understand the downstream immune responses induced by PRR-targeted adjuvants. [4] Soluble vaccine components are typically not sufficiently immunogenic to result in protective immunity. This is primarily because diffusion and clearance of soluble material inhibits the required local concentration of antigen necessary for inducing immune responses.
Particulate systems are inherently more immunogenic than soluble systems, thus soluble vaccine components can be formulated into particulate systems to improve immune responses. [14] Additionally, current fabrication techniques allow nanoscale control and characterization of physicochemical properties, which can significantly affect interactions with the immune system. Particle templating approaches can be exploited for such applications, as they result in high particle uniformity and monodispersity. Porous particles are especially advantageous for their characteristically high surface areas compared with solid particles, 5 which facilitates adsorption of a relatively higher amount of cargo (e.g., antigen, PRR agonist molecules). Mesoporous silica (MS)-mediated polymer particles with tunable size, elasticity, and surface chemistry meet the requirements for these applications. [15] Our previous study showed that ovalbumin (OVA) particles fabricated via MS templating and amide bond crosslinking induced significantly better antigen-specific immune responses in mice compared with soluble OVA. [16] We showed that particles fabricated with reduced OVA induced significantly increased antigen-specific immune responses compared with native analogs, whereas oxidization of OVA resulted in a significant decrease in antigen-specific immune responses.
In this study, NOD2 and TLR9 agonists (muramyl dipeptide (MDP) and CpG oligonucleotides (ODNs), respectively) were chemically conjugated to reduced OVA particles engineered via MS templating. All experimental groups were conjugated with either a positive or negative analog of each agonist, where corresponding analogs share a similar structure and chemical reactivity. Thus, experimental groups maintain consistent physicochemical properties and the roles of NOD2, TLR9, and NOD2/TLR9 combinatorial signaling could be delineated. The results showed that particles containing MDP and CpG had a synergistic effect on cytokine secretion by a mouse macrophage cell line (i.e., RAW 264.7, RAW) compared with particles containing only one PRR agonist, confirming synergistic crosstalk between NOD2 and TLR9 induced by the particle system. Following administration in mice, 
Results and Discussion
In our previous study, we used a MS particle templating approach to show that the reduction of OVA significantly enhanced antigen-specific immune responses compared with native and oxidized analogs. [16] Therefore, reduced OVA particles (abbreviated as OVA particles) fabricated via MS particle templating were rationally selected for functionalization with NOD2 and TLR9 agonists (i.e., MDP and CpG ODNs, respectively). MDP is the minimal bioactive peptidoglycan (PGN) motif common to all bacteria (Scheme S1a). The adjuvant activity of MDP is highly stereospecific, where the L-D isomer is recognized and not the D-D or L-L analogs. [17] Therefore, a stereoisomer of the L-D isomer was used as the negative control (Scheme S1b). Notably, MDP has also been implicated in the activation of the NALP3 inflammasome. [18] TLR9 is an endosomal membrane PRR that recognizes single stranded, unmethylated CpG motifs that are common in viral DNA. In this study, a class B CpG ODN specific for murine TLR9 was selected with a sequence of 5'-TCC ATG ACG TTC CTG ACG TT -3' and a nuclease-resistant phosphorothioate backbone. ODN analogs containing GpC dinucleotides instead of CpG dinucleotides were used as the negative control. Particles were fabricated to contain the four possible combinations using MDP (M+), MDP negative control (M-), CpG ODN (C+), and GpC ODN negative control (C-). In the following sections, particles are referred to as M-C-, M+C-, M-C+, and M+C+ to describe their conjugated ligands. Some experiments also include an additional "naked" group that refers to particles used in our previous study [16] that do not contain conjugated ligands.
Particle Preparation
The four types of particles used in this study (M-C-, M+C-, M-C+, M+C+) were fabricated according to Scheme 1. First, OVA was loaded via electrostatic interactions into aminefunctionalized MS templates with an average diameter of 1 μm and bimodal pore sizes of approximately 2-3 nm and 10-40 nm ( Figure S1a,b) , OVA-loaded MS particles were then treated with a reducing agent, dithiothreitol (DTT), according to our previous study. [16] MDP was covalently conjugated to primary amines present in OVA via amide formation. This was achieved by adding excess MDP to the particle mixture in the presence of 4-(4,6-dimethothy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM), which is a coupling reagent that activates carboxylic acid groups in MDP to form amide bonds with primary amines in OVA. Notably, DMTMM used in this step also stabilized the particles via amide bond formation in OVA. Following treatment with DMTMM, particles were washed and then treated with 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) at pH 8, which reacts with free thiols in OVA resulting in the stoichiometric formation of disulfide bonds in OVA and release of TNB 2- ions. The concentration of TNB 2- ions can be measured by the absorbance of the supernatant at 412 nm to quantify the reaction between DTNB and free thiols in the OVA.
Particles were then extensively washed to remove TNB 2- ions and excess DTNB, ensuring that the disulfides in the OVA were the only thiol reactive species present. Next, CpG ODNs with a thiol attached to the 3' flanking region (referred to as CpG) were added to the system at pH 7.2, which underwent a thiol/disulfide exchange reaction with the disulfide bonds in the OVA. CpG conjugation releases TNB 2- ions into the supernatant also at a 1:1 stoichiometric ratio. Therefore, the moles of TNB ). Using this technique, the conjugated CpG was found to be 3.4 (± 0.8) × 10 -20 moles per particle, which is in good agreement with the value calculated from the TNB 2- concentration. CpG conjugated with FITC at the 5' flanking region was used in the procedure described above and the attachment of CpG was confirmed by visualization of the FITC fluorophore using fluorescence microscopy ( Figure   S2 ). As a result of amide bond formation with DMTMM, stable, freestanding particles were obtained after template removal with HF/NH 4 buffer (pH ~5) ( Figure S1c ). Notably, freestanding particles were not obtained without amide bond formation via treatment with DMTMM. 
NOD2 and TLR9 Activation by Particles
Specific activation of NOD2 and TLR9 by the particles was determined using HEK298 reporter cell lines for NOD2 and TLR9 stimulation (i.e., HEK-mNOD2 and HEK-mTLR9, respectively). HEK293 reporter cell lines are stably transfected to express a secreted embryonic alkaline phosphatase (SEAP) gene that is inducible by PRR activation. HEKmNOD2 and HEK-mTLR9 express high levels of murine NOD2 and TLR9 on the cell surface as well as endogenous levels of TLR3, TLR5, and NOD1. Therefore, parental cell lines (i.e., HEK-Null1, HEK-Null2) that also express the SEAP reporter gene, but are not transfected with NOD2 or TLR9 genes were used as negative controls to verify NOD2 and TLR9-specific responses. Cells were incubated with particles (100:1 particle-to-cell ratio, 24 h) and the SEAP in the supernatant was measured using QUANTI-Blue. Results showed that M+C-and 
Inflammatory Responses in Mouse Macrophages
NF-κB activation is implicated in both TLR and NOD signaling pathways. Particle-induced activation of NF-κB in mouse macrophages was determined using the RAW-Blue reporter cell line, which expresses both TLR9 and NOD2 in their native locations (i.e., endosome and cytoplasm, respectively). This technique is commonly used to measure PRR-associated inflammatory responses induced by other systems, including particulate systems carrying PRR agonists. [19] Cells were incubated with particles (100:1 particle-to-cell ratio, 24 h) and the SEAP in the supernatant was measured using QUANTI-Blue (Figure 2 ). Both M+C-and M-C+ particles induced activation that was significantly higher than M-C-and naked particles (p < 0.001) and M+C+ particles induced activation significantly higher than both M+C-and M-C+ particles (p < 0.001). Thus, simultaneous stimulation of NOD2 and TLR9 in the same cell increased activation of NF-κB, indicating that the intracellular pathways activated by these receptors do not inhibit each other. Our data corroborates a similar finding where a TLR2/NOD2 chimeric ligand induced an additive activation effect in macrophages compared with single NOD2 and TLR2 ligands. [13] Pro-inflammatory responses induced by MDP [19, 20] or CpG ODN [21] delivered individually in particle-based systems have also been observed in other studies (i.e., not combined such as in the current study). Taken together, the results confirm that the OVA particles are an effective delivery system for NOD2 and TLR9 agonists and codelivery enhances NF-κB activation in macrophages. by optical density at 620 nm of SEAP secretion. Cells were incubated with particles at a particle-to-cell ratio of 100:1 for 24 h at 37 °C, 5% CO 2 . Data are expressed as mean ± standard deviation; *p < 0.05, **p < 0.01, ***p < 0.001 (one-way ANOVA, Bonferroni multiple comparisons test). Data are representative of five independent experiments.
The concentrations of various cytokines secreted by macrophage (RAW) cells incubated with particles (100:1 particle-to-cell ratio, 24 h) were measured using a Bio-Plex assay (Figure 3) . M+C-and M-C+ particles induced significantly more TNF-α secretion than M-Cand naked particles (p < 0.001); and M+C+ particles induced significantly more TNF-α secretion than M+C-and M-C+ particles (p < 0.001). Thus, costimulation of NOD2 and TLR9 enhanced TNF-α secretion, but not synergistically. However, costimulation did synergize the secretion of IL-1β, IL-10, and GM-CSF. This is in agreement with other studies that have demonstrated enhanced and synergistic cytokine secretion induced by TLR and NOD receptors. [3, 12, 13] The specific molecular mechanism responsible for the synergistic effect of NOD agonists on TLR-mediated cytokine production is unclear. [22, 23] However, it has been shown that NOD2 stimulation upregulates MyD88 expression. [24] TAK1, a molecule involved in MyD88-dependent TLR signaling has also been shown to participate in the NOD2 pathway, [25] which may be implicated in the observed synergy. It is also possible that a variety of different mechanisms contribute to NOD/TLR synergy and that not a single mechanism is responsible for the overall effect. [22] 13 One interesting aspect of the data shown in Figure 3 is the synergistic secretion of IL-1β.
The secretion of IL-1β is a cytokine associated with activation of the caspase-1 inflammasome, which processes intracellular pro IL-1β and IL-18 into their bioactive forms.
RAW cells, however, do not express the ASC adaptor molecule necessary for activating caspase-1, and therefore cannot produce bioactive IL-1β or IL-18. [26] Typically in the absence of caspase-1 activation, very little pro IL-1β and IL-18 is secreted and most is degraded within the cell. [27] Pelegrin et al., however, showed that stimulation with LPS (TLR4 agonist) and ATP (NLRP3 agonist) induced secretion of the pro-IL-1β precursor by RAW cells, [26] suggesting that NLRP3 activation can facilitate the release of the pro IL-1β from RAW cells through a caspase-1-independent mechanism. It is likely that a similar mechanism occurred in the current experimental setup. However, MDP also activates NLRP3, [18] and so it is unknown whether the current results reflect NOD2-or NLRP3-mediated release of the pro IL-1β.
CD4+ T cell Activation In Vivo
To measure adaptive immune responses induced by the particles in vivo, mice were immunized with particles intraperitoneally (day 0) and then subcutaneously (day 21). Three weeks (day 42) after the secondary immunization, CD4+ T cells were isolated from spleens and proliferation in response to OVA protein was determined, as we described previously (Figure 4a ). [16] Values for each group were normalized by dividing the cell count measured in 
Serum Antibody Production
In mice, a predominant production of sera IgG1 is often associated with Th2-polarized adaptive immune responses, while Th1-mediated responses are associated with predominantly IgG2 and IgG3 production. Mice were bled three weeks after the secondary immunization and the OVA-specific total IgG, IgG1, IgG2a, IgG2b, and IgG3 levels in the sera were measured by ELISA (Figure 5) . Notably, none of the particles induced significant IgG2a or IgG3 production. M+C-, M-C+, and M+C+ particles induced significantly more IgG production than M-C-and naked particles (p < 0.001), but there were no significant differences in the total IgG titer across these three groups (Figure 5a ). Only M+C-(p < 0.01) and M+C+ (p < 0.05) particles induced significant IgG1 production compared with M-C-and naked particles (Figure 5b ), which is consistent with Th2-polarization observed in CD4+ T cell responses (Figure 4b,d,e) . M-C+ and M+C+ induced significant IgG2b production compared with M-Cand naked particles (p < 0.001). Additionally, M+C+ particles induced significantly more IgG2b production than M-C+ particles (p < 0.05). These results are also consistent with Th1-polarization observed in M+C-CD4+ T cells, which was enhanced in M+C+ CD4+ T cells (Figure 4c,f) . Given the agreement between the polarization of CD4+ T cell responses and antibody production, it is likely that B cell activation was largely facilitated by activated CD4+ T cells. However, B cells can also be activated by direct engagement of PRRs. [28, 29] It has been shown that CpG can act directly on B cells to enhance IgG2 responses and suppress IgG1 [30] and that NOD activation can enhance TLR-driven proliferation of B cells. [29] Therefore, antibody production may also reflect intrinsic PRR signaling in B cells. Pavot et al. showed that a NOD2/TLR2 chimeric ligand could synergistically enhance the total sera IgG, IgG1, IgG2a, and IgA with polarization towards Th1-characteristic IgG2a. [13] Our data also show that coactivation of TLR9 and NOD2 enhances Th1-characteristic antibody responses (i.e., IgG2b). This data, in addition to the data in Figure 4 , clearly indicates a different role of NOD2 signaling in polarizing CD4+ T cell and antibody responses that depends on coactivation by TLR9. 
CD8+ T cell and CTL Activation In Vivo
The ability of PRR and OVA loaded particles to induce an OVA-specific CD8+ T cell response in vivo was measured using a variety of assays. CD8+ T cells were isolated from spleens of immunized mice and the OVA-specific IFN- response was determined by ELISPOT. CD8+ T cells from M-C+ (p < 0.01) and M+C+ (p < 0.05) groups were significantly restimulated by OVA protein ex vivo (Figure 6a, black versus white bars) .
Notably, the number of IFN--secreting CD8+ T cells was more significant in the M-C+ group than in the M+C+ group (p < 0.01 versus p < 0.05). Thus, the results may indicate that NOD2 signaling inhibits CD8+ T cell responses. Using a fluorescent tetramer of MHC class I molecules loaded with OVA epitopes (SIINFEKL), the number of OVA-specific CD8+ T cells in the total CD8+ T cell population of each immunized group was quantified (Figure 6b ). The M-C+ particle-immunized group had a significantly higher number of OVA-specific 19 CD8+ T cells compared with all other particle-immunized groups, which all had similarly low numbers of OVA-specific CD8+ T cells. The ability of each particle to prime an in vivo CTL response was determined by administering a mixture of target and control splenocytes 6 days after the booster immunization via intravenous tail vein injection. The OVA-specific cell lysis (i.e., the change in the proportion of target to control splenocytes) was determined 18 h later by flow cytometry using a previously described method [31] ( Figure 6c ). Although the differences across particles are not considered statistically significant, the data clearly indicate reduced CTL activity in mice immunized with both M+C-and M+C+ particles. These results are further evidence supporting the hypothesis that NOD2 signaling inhibits CD8+ T cell responses. CD4+ T cells are known to mediate CD8+ T cell activation through costimulation (i.e., "licensing") of dendritic cells (DCs), which influences the antigen presentation and costimulatory capacity necessary for activating primary CD8+ T cell responses. [32] The results suggest that the CD4+ T cell polarization that occurs due to NOD2/TLR9 signaling is associated with reduced CD8+ T cell activation. CD8+ T cell activation requires MHC class I presentation of particles, which were likely to be internalized by cells via endocytosis/phagocytosis. Several studies have demonstrated that TLR9 signaling with CpG can induce cross presentation of antigens in vitro and CD8+ T cell activation in vivo, [9, 33] which is in agreement with the current studies. A recent study reported by Wagner et al. showed that NOD2 signaling inhibits cross presentation driven by LPS (TLR4 ligand), [34] which is also in agreement with the current results. While the mechanisms are not clear, it is evident that NOD2 activation alone is insufficient to induce a strong CTL response and has a negative effect on TLR9-driven CTL responses.
Conclusion
Reduced ovalbumin particles were rationally selected for functionalization with NOD2 and TLR9 agonists with the aim of enhancing immune responses through synergistic NOD and TLR signaling. NOD2 agonist, MDP, was conjugated to amines in OVA via amide bond formation and TLR9 agonist, CpG ODN, was covalently conjugated to free thiols in reduced OVA via thiol/disulfide exchange. The results showed that the combination of agonists induced synergistic inflammatory innate immune responses but had different effects on 21 adaptive immune responses in vivo. Specifically, NOD2 and TLR9 signaling induced Th2-and Th1-polarized CD4+ T cell and antibody responses, respectively, when delivered as single ligands. TLR9 signaling also induced CD8+ T cell responses. However, when the agonists were combined, enhanced Th1-polarized CD4+ T cell and antibody responses and decreased CD8+ T cell responses were observed.
The study demonstrates that NOD2 signaling can have different roles in modulating the adaptive immune response depending on the presence of TLR9 costimulation. In the absence of TLR9 signaling, NOD2 signaling leads to strongly polarized Th2 responses, which are also induced by current alum and emulsion adjuvants. However, in the presence of TLR9 costimulation, NOD2 signaling can significantly polarize away from Th2 and toward Th1 CD4+ T cell and antibody responses as well as suppress CD8+ T cell responses, whereas TLR9 signaling alone results in a Th1-and CD8+ T cell-mediated responses. A long-term goal in vaccinology is an understanding of how to rationally induce specific types of adaptive immune response, as the characteristics of desired adaptive immune responses vary across vaccine applications. The study shows that NOD2 signaling may be a promising strategy for enhancing TLR-driven Th1 CD4+ T cell and antibody responses while suppressing CD8+ T cell responses, which is valuable knowledge for rational adjuvant formulation. 
Experimental Section

Preparation and Amine-Functionalization of MS Templates. MS particles were synthesized
according to a modified literature method. [35] Briefly , 
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3H-thymidine was added after ~70 h of incubation at 37 °C, 5% CO 2 . 3H-thymidine incorporation was assessed using a beta counter 24 h later (i.e., ~94 h incubation total). In Vivo CTL Assay. In vivo cytotoxic T cell activity was determined using the method described by Mueller et al. [31] Target and control splenocyte cells were prepared from donor naïve mice. Target splenocytes were pulsed/incubated in media without FBS (1 hour, 37 °C) (wt/vol) skim milk powder from 1/12.5 to 1/1600 were added to wells and incubated overnight at 4 °C. Wells were washed three times with PBS-T and once with PBS and incubated with goat anti-mouse (2.5% skim milk/PBS) directed against total IgG (1/4000 dilution) for 1 h at room temperature. Wells were washed three times with PBS-T and once with PBS and bound antibody was detected by incubation with horseradish peroxidaseconjugated swine anti-goat (1/4000 dilution) for 1 h at room temperature. Wells were washed three times with PBS-T and once with PBS. Substrate, ABTS in 50 mM citric acid buffer containing 0.02% (vol/vol) hydrogen peroxide was added. After incubation for approximately 1 h, optical density at 405 nm was measured using a microplate reader.
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